Patents by Inventor Joerg Bentzien

Joerg Bentzien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20210009567
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: July 23, 2020
    Publication date: January 14, 2021
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 10875852
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: December 29, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joerg Bentzien, Angela Kay Berry, Todd Bosanac, Michael Jason Burke, Darren Todd Disalvo, Joshua Courtney Horan, Shuang Liang, Can Mao, Wang Mao, Yue Shen, Fariba Soleymanzadeh, Renee M. Zindell
  • Isoquinolones as BTK inhibitors
    Patent number: 10570118
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: February 25, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Todd Bosanac, Joerg Bentzien, Michael Jason Burke, Darren Todd DiSalvo, Wang Mao, Fariba Soleymanzadeh, John A. Westbrook, Zhaoming Xiong
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20200055843
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: August 29, 2019
    Publication date: February 20, 2020
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20190112302
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Application
    Filed: October 15, 2018
    Publication date: April 18, 2019
    Inventors: Joerg BENTZIEN, Angela Kay BERRY, Todd BOSANAC, Michael Jason BURKE, Darren Todd DISALVO, Joshua Courtney HORAN, Shuang LIANG, Can MAO, Wang MAO, Yue SHEN, Fariba SOLEYMANZADEH, Renee M. ZINDELL
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20190092759
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: September 21, 2018
    Publication date: March 28, 2019
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • ISOQUINOLONES AS BTK INHIBITORS
    Publication number: 20190023686
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: January 12, 2017
    Publication date: January 24, 2019
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Darren Todd DISALVO, Wang MAO, Fariba SOLEYMANZADEH, John A. WESTBROOK, Zhaoming XIONG
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 10138229
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: November 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joerg Bentzien, Angela Kay Berry, Todd Bosanac, Michael Jason Burke, Darren Todd Disalvo, Joshua Courtney Horan, Shuang Liang, Can Mao, Wang Mao, Yue Shen, Fariba Soleymanzadeh, Renee M. Zindell
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20180222893
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: April 9, 2018
    Publication date: August 9, 2018
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 9975882
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: May 22, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Todd Bosanac, Joerg Bentzien, Michael Jason Burke, Ryan Michael Fryer, Eric Thomas Larson, Wang Mao, Bryan Patrick McKibben, Yue Shen, Fariba Soleymanzadeh, Matt Aaron Tschantz
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20180086748
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Application
    Filed: November 16, 2017
    Publication date: March 29, 2018
    Inventors: Joerg BENTZIEN, Angela Kay BERRY, Todd BOSANAC, Michael Jason BURKE, Darren Todd DISALVO, Joshua Courtney HORAN, Shuang LIANG, Can MAO, Wang MAO, Yue SHEN, Fariba SOLEYMANZADEH, Renee M. ZINDELL
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20180030037
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 1, 2018
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • Pyrazole compounds as BTK inhibitors
    Patent number: 9828364
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy, and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: November 28, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joerg Bentzien, Angela Kay Berry, Todd Bosanac, Michael Jason Burke, Darren Todd Disalvo, Can Mao, Wang Mao, Yue Shen
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 9815822
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: November 14, 2017
    Assignee: Boehringer Ingelheim Internatinal GmbH
    Inventors: Todd Bosanac, Joerg Bentzien, Michael Jason Burke, Ryan Michael Fryer, Eric Thomas Larson, Wang Mao, Bryan Patrick McKibben, Yue Shen, Fariba Soleymanzadeh, Matt Aaron Tschantz
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20170174663
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: December 15, 2016
    Publication date: June 22, 2017
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • PYRAZOLE COMPOUNDS AS BTK INHIBITORS
    Publication number: 20160340339
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy, and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Application
    Filed: January 23, 2015
    Publication date: November 24, 2016
    Inventors: Joerg BENTZIEN, Angela Kay BERRY, Todd BOSANAC, Michael Jason BURKE, Darren Todd DISALVO, Can MAO, Wang MAO, Yue SHEN
  • Protein design automation for protein libraries
    Patent number: 7379822
    Abstract: The invention relates to the use of protein design automation (PDA) to generate computationally prescreened secondary libraries of proteins, and to methods and compositions utilizing the libraries.
    Type: Grant
    Filed: September 18, 2003
    Date of Patent: May 27, 2008
    Assignee: Xencor
    Inventors: Bassil I. Dahiyat, Robert J. Hayes, Jöerg Bentzien, Klaus M. Fiebig
  • Protein design automation for protein libraries
    Patent number: 7315786
    Abstract: The invention relates to the use of protein design automation (P DA) to generate computationally prescreened secondary libraries of proteins, and to methods and compositions utilizing the libraries.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: January 1, 2008
    Assignee: Xencor
    Inventors: Bassil I. Dahiyat, Jörg Bentzien, Klaus M. Fiebig, Robert J. Hayes
  • Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    Publication number: 20070060633
    Abstract: Compounds of Formula (IA) and (IB) wherein R1, R2, R3, A, B, C, D, and E are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Application
    Filed: June 8, 2006
    Publication date: March 15, 2007
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Ingo Mugge, David Thomson, Abdelhakim Hammach, Michael Burke, Mark Ralph, Jennifer Kowalski, Joerg Bentzien
  • Crystal structure of the ITK kinase domain
    Publication number: 20070032403
    Abstract: Disclosed are polypeptides encoding the ITK kinase domain and nucleic acids encoding such polypeptides, crystal structures of various polypeptide-ligand complexes comprising the ITK kinase domain bound to a ligand, methods of producing the aforementioned polypeptides and nucleic acids which encode them and methods of producing crystal structures of the aforementioned polypeptides comprising the ITK kinase domain bound to a ligand.
    Type: Application
    Filed: December 23, 2004
    Publication date: February 8, 2007
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Joerg Bentzien, Bennett Farmer, Steven Pullen, Joey Studts, Andre White